Open ICICI
3-in-1 Account
Manage your Savings, Demat and Trading Account conveniently at one place
Manage your Savings, Demat and Trading Account conveniently at one place
News: Eugia, a unit of India’s Aurobindo, has issued a voluntary recall of one lot of methocarbamol injection in the US after a customer complained about finding white particles inside a vial. The lot was distributed in the US in January of this year, the company said in a letter posted to the FDA website and dated March 22. Methacrarbamol is used to treat discomfort related to musculoskeletal conditions.
Views: Eugia injectable facilities in Telangana and New Jersey have recently received observations by the USFDA. The company recently had also halted the production at Eugia III facility in Telangana for few days to address certain issues. Eugia III is an important plant for the company with 109 final USFDA approvals from this facility. Injectables account for ~25% of Aurobindo’s US sales (US$ 450 million in Q3). Frequent quality issues and recalls may warrant stringent USFDA actions in the future.
Impact: Negative